DexCom (DXCM) PT Lowered to $62 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
DexCom (DXCM) PT Lowered to $57 at Leerink Partners
September 29, 2017 6:50 AM EDTLeerink Partners analyst Danielle Antalffy lowered her price target on DexCom (NASDAQ: DXCM) to $57.00 (from $85.00) while maintaining an Outperform rating.
Despite increased competition, Antalffy said a pricing sensitivity analysis shows a path to share upside.
... MoreDexCom (DXCM) PT Lowered to $70 at Stephens
September 28, 2017 6:13 AM EDTStephens lowered its price target on DexCom (NASDAQ: DXCM) to $70.00 (from $83.00) while maintaining a Overweight rating.
Analyst Chris Cooley sees the CY 2018 outlook as challenging but expects clearance of G6 and user preference for accuracy and functional CGM data to drive a re-accelerated top-line growth as H2 2018 approaches.
... MoreRaymond James Downgrades DexCom (DXCM) to Market Perform
September 28, 2017 5:05 AM EDTRaymond James downgraded DexCom (NASDAQ: DXCM) from Outperform to Market Perform.
Analyst Jayson Bedford removes his $80.00 price target.
For an analyst ratings summary and ratings history on DexCom click here. For more ratings news on DexCom click here.
Shares of DexCom closed at $67.47 yesterday.
... MoreDexCom (DXCM) PT Lowered to $60 at Barclays
September 28, 2017 5:01 AM EDTBarclays lowered its price target on DexCom (NASDAQ: DXCM) to $60.00 (from $76.00) while maintaining a Equalweight rating.
Analyst Matt Taylor keeps a positive view on the company noting potential to produce exciting developments citing G6 sensors and collaborations with Verily/PODD that... More
DexCom (DXCM) PT Lowered to $64 at Cowen
September 28, 2017 4:58 AM EDTCowen lowered its price target on DexCom (NASDAQ: DXCM) to $64.00 (from $90.00) while maintaining a Outperform rating.
Analyst Doug Schenkel says comments from Abbott (NYSE: ABT) on pricing after receiving approval for Libre creates a... More
DexCom (DXCM) PT Lowered to $69 at Canaccord Genuity
September 28, 2017 3:24 AM EDTCanaccord Genuity lowered its price target on DexCom (NASDAQ: DXCM) to $69.00 (from $90.00) while maintaining a Buy rating.
Analyst Kyle Rose remains buy-rated noting that estimates are now reset. The analyst reduces his forward growth profile estimates by 10% for 2018, 12% for 2019 and 14% for... More
JPMorgan Downgrades DexCom (DXCM) to Neutral
September 28, 2017 3:06 AM EDTJPMorgan downgraded DexCom (NASDAQ: DXCM) from Overweight to Neutral with a price target of $71.00 (from $93.00).
Analyst Mike Weinstein says the Libre label and aggressive pricing strategy puts the company at risk although he continues to still see positives.
FY 2018 EPS estimate falls from... More
DexCom (DXCM) Weakens After FDA Approves Abbott's (ABT) Continuous Glucose Monitoring System
September 27, 2017 5:38 PM EDTWeakness in DexCom (NASDAQ: DXCM) after the market close on Wednesday was tied to news the FDA approved Abbott's (NYSE: ABT) continuous glucose monitoring system for adults not requiring blood sample calibration.
Shares of DexCom traded lower by 13%.
... More